Texas HB5147 amends the Health and Safety Code to regulate investigational stem cell treatments, ensuring they are administered under strict.

Texas HB5147 amends the Health and Safety Code to redefine "investigational stem cell treatment" as an adult stem cell treatment under clinical trial, not yet approved by the FDA, and using only FDA-compliant adult stem cells. It mandates that treatments be administered by certified physicians, overseen by institutional review boards, and provided at specific licensed facilities. Institutional review boards must submit annual reports to the Texas Medical Board on serious adverse events, without patient identifying information. The bill takes effect September 1, 2025.

Texas HB5147 amends the Health and Safety Code to regulate investigational stem cell treatments, ensuring they are administered under strict.

Texas HB5147 amends the Health and Safety Code to redefine "investigational stem cell treatment" as an adult stem cell treatment under clinical trial, not yet approved by the FDA, and using only FDA-compliant adult stem cells. It mandates that treatments be administered by certified physicians, overseen by institutional review boards, and provided at specific licensed facilities. Institutional review boards must submit annual reports to the Texas Medical Board on serious adverse events, without patient identifying information. The bill takes effect September 1, 2025.